- Supported exchanges /
- F /
- 4A3.F
immatics biotechnologies GmbH (4A3 F) stock market data APIs
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
immatics biotechnologies GmbH Financial Data Overview
| 8.64 | |
| 8.32 | |
| - | |
| 8.64 | |
| 8.32 | |
| 7.22-12.9 | |
| 1 071 M | |
| 119 M | |
| 70 871 K | |
| 0.747 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
immatics biotechnologies GmbH Fundamental Data is available in our Financial Data APIs
- Net Revenue 70 871 K
- EBITDA -95 191 000
- Earnings Per Share -0.83
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get immatics biotechnologies GmbH Earnings via APIs
- Latest Release NaN
- EPS/Forecast NaN
Get immatics biotechnologies GmbH End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
